Corporate Sponsored Funding
PIVOT Center works with companies to thoroughly understand their R&D goals and match them to research goals of the appropriate faculty members at the University of Utah. PIVOT’s Corporate Engagement team works across all schools and units to facilitate partnerships and offer expertise on identifying opportunities that include grant funding, sponsored research and creating strategic corporate partnerships. PIVOT also provides guidance to faculty for successful stewardship. Please contact Sadhna Kohli (Director of Corporate Engagement) for more information regarding these opportunities, or if you have any questions.
Alexa AI-Natural Understanding’s (NU) mission is to build and enable engaging, world-class conversational AI capabilities that are broadly accessible. Under this call for proposals, Amazon Research are seeking to fund research projects on the following topics:
- Transparency, explainability, and accountability in AI systems
- Theories of computational/algorithm fairness and factors that affect algorithmic trustworthiness
- Detecting and ameliorating adverse biases in data and algorithms, and fairness-aware design of algorithms
- Metrics and methods for designing, piloting, and evaluating systems that mitigate against adverse biases and ensure fairness, including the use of human-machine collaboration and decision support
Seeking technologies to remove nitrogen from urban stormwater runoff that can be used in combination with existing treatment methods, like bioretention, biofiltration or filtration.
Must-have requirements are:
- Capable of reliably removing at least 50% of total nitrogen from urban stormwater
- Can be deployed in urban stormwater drainage systems
- Does not export pollutants, including sediment, phosphorus, or metals
Preferred requirements are:
- A passive approach that does not require chemical or energy inputs
- Accommodates treatment flow rates in the range of 1-2 gpm per square foot of treatment area
- Capable of removing phosphorus as well as nitrogen
- Projects that will be considered for Pfizer support will focus on development of an algorithm or tool to guide the optimal treatment and support of patients with ALK or ROS1 re-arranged NSCLC.
- The output of the project can be electronic (e.g. EMR-based or Application-based) or paper (e.g. published or freely available to download).
- Therapy-management guidance is needed at all lines of treatment (e.g., first-line 1L, second-line 2L) and should include anticipated and pro-active management of side effects (neurocognitive, lipidemic etc.)
- Support is available to institutions interested in developing a therapy management tool that can used at their own center and also be made widely available to others through publication and other dissemination strategies. It is not our intent to support clinical research projects.
- Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
Projects that will be considered for Pfizer support will focus on educating surgeons and other healthcare professionals on topical hemostasis in minimally invasive surgical (MIS) procedures, addressing knowledge and practice gaps specific to perioperative bleeding during MIS including robotically-assisted procedures. interested in programs that focus on some or all of the following:
- Management of capillary, venous and arteriolar bleeding in MIS
- Preparation and use of topical hemostatic agents in MIS operating room environment
- Delivery of topical hemostatic agents to difficult-to-access & difficult-to-visualize operative sites/sites of bleeding
- Assessment of bleeding severity and effectiveness of topical hemostats in MIS
The overall aim is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. It is hoped proposals submitted in response to this RFP will guide development of enzalutamide and its combination with other therapies. Studies with correlative endpoints will be accepted, and studies that retrospectively analyze biomarkers (tissue, liquid biopsy, and other approaches) within prospective trials or datasets will be accepted.
Only pre-clinical projects with a focus on these areas of interest will be considered for Pfizer support at this time:
- Correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy
- Understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS)
- Mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion)
- Correlation between Soluble BCMA and BCMA expression on myeloma cells
- Impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels
- Mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity
- Exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135) Zuckerman Scholars enjoy unique programming and activities organized especially for them by their host universities and the Zuckerman Institute in Israel, including touring, educational experiences, and social programs. These activities are designed to strengthen the scholars’ knowledge of and connection to Israel, and cultivate an esprit de corps, exchange of ideas, and foster new relationships.
This Request for Applications (RFA) is intended to bring together teams of experts to 1) ethically and appropriately generate data derived from tissues from people whose ancestral groups are historically understudied and thereby expand the ancestral diversity of single-cell data that is available via the HCA, and 2) utilize best practices and build up systems to enable long-term engagement of potential participants and donors from diverse communities to contribute to the current and future drafts of the HCA. This work will help provide insights into the contribution of genetic ancestry to disease now and in the future, resulting in an atlas that may be more generalizable and representative of the diversity found in the global human population.
Primary immunodeficiencies occur in all patient populations but the
diagnoses are infrequently made in minority populations in the US. These
disparities have been noted in several studies. Through this RFP, the intent is to support patient and provider educational programs on the awareness, diagnosis, and treatment of primary immunodeficiencies within minority/underserved populations.
Established in 2016, the Innovators in Science Award is administered by the New York Academy of Sciences and sponsored by Takeda Pharmaceuticals. This global award recognizes a promising Early-Career Scientist's and an outstanding Senior Scientist's contributions to biomedical science and is intended to support their commitment to innovative research.
Two prizes of US$200,000 are awarded each Award cycle to winning scientists who have distinguished themselves for the creativity and impact of their research in a designated therapeutic area.
The intent is to support institutions with fellowship programs for Pediatric Endocrinologists that have a strong focus on clinical practice, research, and education to further the understanding of short stature/growth failure
Research projects that will be considered for Pfizer support will advance the medical knowledge of short stature. Projects submitted may include:
- Diagnostics, early treatment, new treatment paradigms
- Clinical outcomes, quality of life, and patient reported outcomes
- Medication adherence research
- Translational or clinical research
Projects that will be considered for Pfizer support will focus on preparing and/or optimizing multidisciplinary care teams for the integration of gene therapy into the treatment armamentarium for patients with a Rare Disease. Support is available for the development of leadership, best practices, SOP development, site readiness, support and/or training of HCPs within a multidisciplinary team environment to optimize the quality of care for patients who have/will have gene therapy in their treatment armamentarium.
Projects that address recombinant adeno-associated virus gene therapy in Rare Disease and are therapeutic area and disease area agnostic (i.e., platform) will be prioritized. It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
Projects that will be considered for Pfizer support will focus on:
- Morbidity and mortality in Growth Hormone Excess
- Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat Growth Hormone Excess
- Early diagnosis and treatment of Growth Hormone Excess
- Pathophysiology of Growth Hormone Excess
The intent is to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grants will be available for both established and emerging Amyloid Centers of Excellence.
The intent is to support virtual and potentially live programs and other innovative digital medical education for Health Care Professionals. The focus is on Osteoarthritis and Chronic Pain associated with OA and patient-centered standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management. Programs targeted towards reviewing data at virtual or live osteoarthritis, rheumatology, pain, primary care, or other associated medical conferences, including but not limited to OARSI, EULAR, PAINWeek, AAFP, WCO, and ACR are of particular interest, as well as other meaningful education outside of congresses.
Pfizer’s Centers for Therapeutic Innovation (CTI) Call for Proposals (CFP) to share details about our areas of interest and the timeline for submission of non-confidential pre-proposals this round. CTI focuses on accessing cutting-edge science and innovative discoveries aligned with Pfizer’s current core research areas of Oncology, Inflammation & Immunology, Rare Diseases, and Internal Medicine.
- Quarter1 2018 (1)
- April 2019 (26)
- August 2019 (17)
- December 2019 (10)
- February 2019 (25)
- July 2019 (14)
- June 2019 (16)
- March 2019 (17)
- May 2019 (13)
- November 2019 (8)
- October 2019 (20)
- September 2019 (14)
- April 2020 (13)
- August 2020 (10)
- December 2020 (11)
- February 2020 (12)
- January 2020 (10)
- July 2020 (9)
- June 2020 (7)
- March 2020 (30)
- May 2020 (10)
- November 2020 (15)
- October 2020 (21)
- September 2020 (19)
- April 2021 (10)
- August 2021 (21)
- December 2021 (12)
- February 2021 (17)
- January 2021 (10)
- July 2021 (11)
- June 2021 (17)
- March 2021 (21)
- May 2021 (14)
- November 2021 (16)
- October 2021 (15)
- September 2021 (16)
- April 2022 (8)
- February 2022 (14)
- January 2022 (9)
- March 2022 (22)
- May 2022 (14)